TLC has been a customer to AAK since many years and is specialized in extracting phospholipids from egg yolk. These phospholipids have been supplied to the nutrition market under the brand OvoLife.
Phospholipids extracted from egg yolk offer additional benefits when included in nutrition formulas and reinforce functions of the brain, the eyes and the immune system at all life stages. By blending these phospholipids with Akonino®, AAK’s solution for infant formulas, AAK will be able to extend its product range within the infant nutrition market and the nutrition markets in general, with new advanced customer co-developed products. The new products containing extracted egg yolk phospholipids will be branded Akonino® PL.
“Egg phospholipids are important ingredients in nutrition formulas and this investment will help us to expand our infant nutrition portfolio”, says Renald Mackintosh, Chairman of AAK’s Infant Nutrition division. “Today, Akonino® PL is only sold in Europe but our ambition is to expand our sales outside of Europe during the coming years, with focus on Asia.”
The invested amount is not material and the transaction will have a very limited impact on AAK’s short term profitability. The investment is financed well within the existing credit facilities. AAK will continue the operation from the current premises in Bastogne, Belgium and operations will be restarted.
source: aak.com
Phospholipids extracted from egg yolk offer additional benefits when included in nutrition formulas and reinforce functions of the brain, the eyes and the immune system at all life stages. By blending these phospholipids with Akonino®, AAK’s solution for infant formulas, AAK will be able to extend its product range within the infant nutrition market and the nutrition markets in general, with new advanced customer co-developed products. The new products containing extracted egg yolk phospholipids will be branded Akonino® PL.
“Egg phospholipids are important ingredients in nutrition formulas and this investment will help us to expand our infant nutrition portfolio”, says Renald Mackintosh, Chairman of AAK’s Infant Nutrition division. “Today, Akonino® PL is only sold in Europe but our ambition is to expand our sales outside of Europe during the coming years, with focus on Asia.”
The invested amount is not material and the transaction will have a very limited impact on AAK’s short term profitability. The investment is financed well within the existing credit facilities. AAK will continue the operation from the current premises in Bastogne, Belgium and operations will be restarted.
source: aak.com
